(Prostate Cancer) Is Cabometyx Plus Tecentriq Effective? CONTACT-02 Phase 3 Trial Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- August 28, 2023
- 1 min read
On August 22, 2023, Takeda Pharmaceutical announced that cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved progression-free survival (PFS) in metastatic castration-resistant prostate cancer patients.
This announcement is based on interim analysis results from the CONTACT-02 international Phase 3 clinical trial. The CONTACT-02 trial enrolled patients with metastatic castration-resistant prostate cancer who had previously received hormone therapy as first-line treatment. Patients received Cabometyx plus Tecentriq as second-line therapy compared to hormone therapy. Primary endpoints were overall survival (OS) and PFS.
While OS showed an improvement trend in this interim analysis, the data are not yet mature. The study will continue to the next OS analysis.
Safety:
Adverse events for Cabometyx and Tecentriq individually were consistent with the known safety profiles of each agent as monotherapy. No new safety signals were identified with the combination.
Source: https://www.takeda.com/ja-jp/announcements/2023/Cabozantinib_Atezolizumab/
Prostate Cancer | Cabozantinib | Atezolizumab | CONTACT-02
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4